A new drug has been found to slow cognitive and functional decline in people with early symptomatic Alzheimer’s disease (AD), according to the results of the phase 3 clinical trials.

The data about the drug donanemab, developed by American pharmaceutical firm Eli Lilly and Company, was shared at the 2023 Alzheimer’s Association International Conference (AAIC) in the Netherlands, and simultaneously published in the Journal of the American Medical Association (JAMA).

“The positive data bring hope to people with Alzheimer’s disease who urgently need new treatment options,” said Anne White, executive vice president of Eli Lilly and Company.